Literature DB >> 29125026

Delayed and incomplete treatment may result in dural fistula development in children with Vein of Galen malformation.

Dan Meila1, Cynthia Schmidt2, Katharina Melber2, Dominik Grieb2, Cornelius Jacobs3, Collin Jacobs4, Heinrich Lanfermann1, Friedhelm Brassel2.   

Abstract

The association of dural arteriovenous fistulas (DAVF) in children with Vein of Galen malformation (VGM) has recently been reported for the first time. In a larger series of cases treated with transarterial NBCA embolization, 30% had DAVF. We wanted to analyze the development of DAVF in our cohort of children with VGM and to evaluate whether their occurrence depends on different treatment timing and embolic materials. We analyzed 43 VGM cases treated with a combined transarterial and transvenous approach between 2003 and 2016. In our early series until 2011, we used coils solely in 21 children. Since 2012, 22 children were treated with the combination of coils and Onyx. In the early series treated with coils solely, no case presented initially with or developed DAVF over time on follow-up angiograms. In our recent series we found four cases (9%) with DAVF. In two patients (5%), DAVF were found on the initial angiogram. Both patients presented at our department at age >2 years and were not treated elsewhere before. One patient (2%) presented at our department with too proximal occlusion of arterial feeders performed at another institution before. Only one patient (2%) developed DAVF in our department after the transarterial use of Onyx. Interestingly, this child did not develop DAVF as long as we used coils solely and his DAVF was localized exactly where an Onyx cast was identified. In conclusion, delayed and incomplete treatment may have a considerable impact on the occurrence of DAVF in VGM.

Entities:  

Keywords:  Onyx; Vein of Galen malformation; coiling; dural arteriovenous fistula; embolization

Mesh:

Substances:

Year:  2017        PMID: 29125026      PMCID: PMC5772547          DOI: 10.1177/1591019917741755

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  7 in total

1.  Expression of angiogenic growth factors in dural arteriovenous fistula.

Authors:  R Uranishi; H Nakase; T Sakaki
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

Review 2.  The management of vein of Galen aneurysmal malformations.

Authors:  Pierre L Lasjaunias; Soke M Chng; Marina Sachet; Hortensia Alvarez; Georges Rodesch; Ricardo Garcia-Monaco
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

3.  Hydrocephalus in vein of Galen malformation: etiologies and therapeutic management implications.

Authors:  Dan Meila; Dominik Grieb; Katharina Melber; Collin Jacobs; Homajoun Maslehaty; Athanasios Petridis; Rashad El Habony; Heinrich Lanfermann; Martin Scholz; Friedhelm Brassel
Journal:  Acta Neurochir (Wien)       Date:  2016-05-13       Impact factor: 2.216

4.  Vein of Galen malformations in neonates: new management paradigms for improving outcomes.

Authors:  Alex Berenstein; Johanna T Fifi; Yasunari Niimi; Salvatore Presti; Rafael Ortiz; Saadi Ghatan; Barak Rosenn; Michelle Sorscher; Walter Molofsky
Journal:  Neurosurgery       Date:  2012-05       Impact factor: 4.654

5.  Vein of Galen aneurysmal malformation: combined transvenous and transarterial method using a "kissing microcatheter technique".

Authors:  Dan Meila; Raphaela Hannak; Axel Feldkamp; Martin Schlunz-Hendann; Andreas Mangold; Collin Jacobs; Karsten Papke; Friedhelm Brassel
Journal:  Neuroradiology       Date:  2011-04-01       Impact factor: 2.804

6.  Dural arteriovenous shunt development in patients with vein of galen malformation.

Authors:  Srinivasan Paramasivam; Yasunari Niimi; Dan Meila; Alejandro Berenstein
Journal:  Interv Neuroradiol       Date:  2014-12-05       Impact factor: 1.610

7.  Investigation of the mechanism of dural arteriovenous fistula formation induced by high intracranial venous pressure in a rabbit model.

Authors:  Shou-Sen Wang; Chang-Hua Li; Xiao-Jun Zhang; Ru-Mi Wang
Journal:  BMC Neurosci       Date:  2014-08-27       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.